content

OTEZLA® (Apremilast) Phase II Data Showed Clinically significant Improvements in Patients with Active Ulcerative Colitis

Celgene Corporation announced that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active ulcerative colitis who had...

OTEZLA (Apremilast) Phase III Data Showed good results among Patients with Active Behçet’s Disease with Oral Ulcers

Celgene Corporation announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet's Disease with oral ulcers...

Bristol-Myers Squibb and Nektar Therapeutics to collaborate for Nektar’s CD122-biased Agonist, NKTR-214

Bristol-Myers Squibb Company announced the companies have executed a global strategic development and commercialization collaboration for Nektar’s lead immuno-oncology program, NKTR-214. ...

Process Considerations for Cryogenic and Regenerative Medicine Commercialization

McKesson, Fisher BioServices, GE Healthcare and Cryoport are proud to announce our first annual workshop. Our FREE two-day workshop will provide a forum for...

Saneca Pharma appoints new CEO

Contract development and manufacturing organisation (CDMO) Saneca Pharma has announced the appointment of its new CEO, Richard Král. Richard, who has...

Amgen sets up a FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO

Amgen announced that the Oncologic Drugs Advisory Committee of the U.S. FDA will review data supporting the BLINCYTO® (blinatumomab) supplemental Biologics License Application (sBLA)...

AbbVie presents New, Late Breaking Investigational Data at 2018 at AAD Annual meeting

AbbVie  a global research and development-based biopharmaceutical company, today announced it will present new, late-breaking data across investigational medicines and HUMIRA® (adalimumab) at the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read